Literature DB >> 30273483

Building Block Based Construction of Membrane-Organelle Double Targeted Nanosystem for Two-Drug Delivery.

Rafael R Castillo1,2, Daniel Lozano1,2, María Vallet-Regí1,2,3.   

Abstract

Despite the claim that encapsulation of drugs improves the therapeutic profile of free drugs, there are still important limitations in drug delivery. With respect to cancer treatment, two promising implementations are combination therapy and targeted devices, which are aimed at increasing the drug effect either by achieving higher cell death rates or by discriminating between cell populations. However, for the time being, the scope of combining both approaches is unknown. To advance this knowledge, a two-drug-delivery system with dual cell-organelle targeting based on mesoporous silica nanoparticles, which are known to be able to host drugs within their pores, has been designed. In vitro results show a synergistic effect and high efficacy, demonstrating that the combination of dual therapy and targeting could still advance the development of drug-delivery nanodevices against difficult-to-treat cancers.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30273483     DOI: 10.1021/acs.bioconjchem.8b00603

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  3 in total

Review 1.  Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.

Authors:  Rafael R Castillo; Daniel Lozano; Blanca González; Miguel Manzano; Isabel Izquierdo-Barba; María Vallet-Regí
Journal:  Expert Opin Drug Deliv       Date:  2019-04-22       Impact factor: 6.648

Review 2.  Recent Development of Drug Delivery Systems through Microfluidics: From Synthesis to Evaluation.

Authors:  Zhiyuan Ma; Baicheng Li; Jie Peng; Dan Gao
Journal:  Pharmaceutics       Date:  2022-02-17       Impact factor: 6.321

Review 3.  Chronology of Global Success: 20 Years of Prof Vallet-Regí Solving Questions.

Authors:  Miguel Manzano
Journal:  Pharmaceutics       Date:  2021-12-17       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.